Actively Recruiting
Melatonin for Prevention of Kidney Injury
Led by Rutgers, The State University of New Jersey · Updated on 2025-12-17
300
Participants Needed
2
Research Sites
238 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the safety and effectiveness of melatonin for the prevention of antibiotic associated acute kidney injury in hospitalized patients.
CONDITIONS
Official Title
Melatonin for Prevention of Kidney Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 75 years
- Currently prescribed vancomycin with the plan to continue therapy for at least 3 days
- One dose of vancomycin and piperacillin/tazobactam allowed before consent and enrollment due to urgent treatment needs
You will not qualify if you...
- Estimated creatinine clearance less than 30 mL/min
- Liver impairment with liver enzymes greater than three times the upper limit
- History of allergy or contraindication to melatonin
- Pregnancy or breastfeeding
- Autoimmune disease
- Requiring vasopressors
- Requiring mechanical ventilation
- History of acute kidney injury in the past 30 days
- Inability to take oral medications
- Significant unstable or uncontrolled illness that could affect study results or safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
2
Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey, United States, 08876
Actively Recruiting
Research Team
L
Luigi Brunetti, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here